( ncouraging signs of therapeutic activi...)Protox Announces Positive Clinical Data from Prostate Cancer Study,Health

ncouraging signs of therapeutic activity were observed.

No significant safety issues relating to PRX302 treatment were encountered in this clinical trial. One patient in the study, who met inclusion criteria in spite of having borderline liver abnormalities, showed a transient rise in liver enzymes (Grade 3 on the National Cancer Institute's 5-stage grading scale) that quickly returned to screening levels. An expanded cohort was enrolled at this dose in order to collect additional safety data. No safety issues were observed in any patients within the expanded cohort or in further cohorts that received higher doses. In summary, no serious adverse events were reported relating to PRX302 and all other adverse events reported were mostly associated with the injection procedure, rating no higher than Grade 1 (mild).

Assessment of potential therapeutic activity was determined by measuring PSA levels throughout the study and conducting prostate biopsies at 30 days post-treatment. PSA is one of the most widely recognized disease markers in prostate cancer and levels of PSA in the blood are used in the diagnosis of prostate cancer, monitoring cancer progression and tracking patient responses to its treatment.

A comparison of prostate biopsies taken at baseline and at 30 days post-treatment shows that 18 of the 24 patients tested in this trial had a decrease in the percentage of cancer-positive biopsies. Three of the patients showed a complete absence of cancer in their day 30 biopsy.

Two specific measurement indicators, PSA doubling time (PSADT) and PSA velocity (PSAV), are key parameters in predicting clinical progression, metastasis and mortality in patients with prostate cancer. Of the 24 patients tested in this study, 90 day PSA data is available for 15 patients at this time. Comparison of PSA levels pre- and post-treatment shows a clear and desirable trend towards an incr
'"/>




Page: 1 2 3 4 5
Related medicine technology :

1. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product